These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 20683637)

  • 41. Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia.
    Walker AR; Klisovic R; Johnston JS; Jiang Y; Geyer S; Kefauver C; Binkley P; Byrd JC; Grever MR; Garzon R; Phelps MA; Marcucci G; Blum KA; Blum W
    Leuk Lymphoma; 2013 Sep; 54(9):1996-2002. PubMed ID: 23256542
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of 17-allylamino-17-demethoxygeldanamycin alone or in combination with paclitaxel on anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Endocrine; 2015 Apr; 48(3):886-93. PubMed ID: 25096912
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.
    Richardson PG; Badros AZ; Jagannath S; Tarantolo S; Wolf JL; Albitar M; Berman D; Messina M; Anderson KC
    Br J Haematol; 2010 Aug; 150(4):428-37. PubMed ID: 20618338
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment.
    Talaei S; Mellatyar H; Asadi A; Akbarzadeh A; Sheervalilou R; Zarghami N
    Chem Biol Drug Des; 2019 May; 93(5):760-786. PubMed ID: 30697932
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study.
    Pedersen KS; Kim GP; Foster NR; Wang-Gillam A; Erlichman C; McWilliams RR
    Invest New Drugs; 2015 Aug; 33(4):963-8. PubMed ID: 25952464
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors.
    Chai RC; Vieusseux JL; Lang BJ; Nguyen CH; Kouspou MM; Britt KL; Price JT
    Mol Oncol; 2017 May; 11(5):567-583. PubMed ID: 28306192
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.
    Wagner AJ; Chugh R; Rosen LS; Morgan JA; George S; Gordon M; Dunbar J; Normant E; Grayzel D; Demetri GD
    Clin Cancer Res; 2013 Nov; 19(21):6020-9. PubMed ID: 24045182
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Formulation and in vitro evaluation of 17-allyamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric mixed micelles for glioblastoma multiforme.
    Saxena V; Hussain MD
    Colloids Surf B Biointerfaces; 2013 Dec; 112():350-5. PubMed ID: 24012704
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients.
    Homsi J; Bedikian AY; Kim KB; Papadopoulos NE; Hwu WJ; Mahoney SL; Hwu P
    Melanoma Res; 2009 Aug; 19(4):238-42. PubMed ID: 19521262
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells.
    Zhang T; Li Y; Zhu Z; Gu M; Newman B; Sun D
    Mol Pharm; 2010 Oct; 7(5):1576-84. PubMed ID: 20669973
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors.
    Ramanathan RK; Egorin MJ; Erlichman C; Remick SC; Ramalingam SS; Naret C; Holleran JL; TenEyck CJ; Ivy SP; Belani CP
    J Clin Oncol; 2010 Mar; 28(9):1520-6. PubMed ID: 20177028
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.
    Sydor JR; Normant E; Pien CS; Porter JR; Ge J; Grenier L; Pak RH; Ali JA; Dembski MS; Hudak J; Patterson J; Penders C; Pink M; Read MA; Sang J; Woodward C; Zhang Y; Grayzel DS; Wright J; Barrett JA; Palombella VJ; Adams J; Tong JK
    Proc Natl Acad Sci U S A; 2006 Nov; 103(46):17408-13. PubMed ID: 17090671
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies.
    Banerji U; O'Donnell A; Scurr M; Pacey S; Stapleton S; Asad Y; Simmons L; Maloney A; Raynaud F; Campbell M; Walton M; Lakhani S; Kaye S; Workman P; Judson I
    J Clin Oncol; 2005 Jun; 23(18):4152-61. PubMed ID: 15961763
    [TBL] [Abstract][Full Text] [Related]  

  • 54. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity.
    Zhang H; Yang YC; Zhang L; Fan J; Chung D; Choi D; Grecko R; Timony G; Karjian P; Boehm M; Burrows F
    Int J Cancer; 2007 Feb; 120(4):918-26. PubMed ID: 17131314
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immune expression and inhibition of heat shock protein 90 in uveal melanoma.
    Faingold D; Marshall JC; Antecka E; Di Cesare S; Odashiro AN; Bakalian S; Fernandes BF; Burnier MN
    Clin Cancer Res; 2008 Feb; 14(3):847-55. PubMed ID: 18245548
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Wu X; Wanders A; Wardega P; Tinge B; Gedda L; Bergstrom S; Sooman L; Gullbo J; Bergqvist M; Hesselius P; Lennartsson J; Ekman S
    Br J Cancer; 2009 Jan; 100(2):334-43. PubMed ID: 19142186
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Heat Shock Protein 90 Inhibitor Decreases Collagen Synthesis of Keloid Fibroblasts and Attenuates the Extracellular Matrix on the Keloid Spheroid Model.
    Lee WJ; Lee JH; Ahn HM; Song SY; Kim YO; Lew DH; Yun CO
    Plast Reconstr Surg; 2015 Sep; 136(3):328e-337e. PubMed ID: 26313837
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
    Weng SH; Tseng SC; Huang YC; Chen HJ; Lin YW
    Biochem Pharmacol; 2012 Jul; 84(1):126-36. PubMed ID: 22480737
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modulation of Hsp90 function in neurodegenerative disorders: a molecular-targeted therapy against disease-causing protein.
    Waza M; Adachi H; Katsuno M; Minamiyama M; Tanaka F; Doyu M; Sobue G
    J Mol Med (Berl); 2006 Aug; 84(8):635-46. PubMed ID: 16741751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.